Mengqi Shi

Notable Publications: Wen X, Wang R, Xu P, et al. Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [(68)Ga]Ga-RGD-RM26-03. Eur J Nucl Med Mol Imaging. 2024. doi: 10.1007/s00259-024-06634-9.

Wen X, Xu P, Shi M, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022;12:422-433. doi: 10.7150/thno.64435.

Zang J, Wen X, Lin R, et al. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [(68)Ga]Ga-FAPI-RGD. Theranostics. 2022;12:7180-7190. doi: 10.7150/thno.72358.

Shi M, Jakobsson V, Greifenstein L, et al. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. Front Med (Lausanne). 2022;9:1034315. doi: 10.3389/fmed.2022.1034315.

Wen X, Zeng X, Shi C, et al. Optimum combination of radiopharmaceuticals-based targeting-triggering-therapy effect and PD-L1 blockade immunotherapy. Adv Ther. 2022;6:2200193. doi: 10.1002/adtp.202200193.